Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
Molecular function of macrophage migration inhibitory factor and a novel therapy for inflammatory bowel disease
Article first published online: 10 OCT 2012
© 2012 New York Academy of Sciences.
Annals of the New York Academy of Sciences
Volume 1271, Nutrition and Physical Activity in Aging, Obesity, and Cancer pages 53–57, October 2012
How to Cite
Nishihira, J. (2012), Molecular function of macrophage migration inhibitory factor and a novel therapy for inflammatory bowel disease. Annals of the New York Academy of Sciences, 1271: 53–57. doi: 10.1111/j.1749-6632.2012.06735.x
- Issue published online: 10 OCT 2012
- Article first published online: 10 OCT 2012
- Crohn’s disease;
- inflammatory bowel disease;
- macrophage migration inhibitory factor;
- ulcerative colitis
Macrophage migration inhibitory factor (MIF) is a unique protein that participates in inflammation, immune responses, and cell growth. An array of in vitro and in vivo experiments has demonstrated that MIF is profoundly involved in the pathogenesis of acute and chronic inflammatory disorders, such as inflammatory bowel disease (IBD). Blockade of MIF bioactivities by either neutralizing anti-MIF antibodies or antagonists prevents inflammatory cytokine cascade, which strongly suggests that an anti-MIF therapeutic strategy is feasible for treatment of IBD. Recently, we developed a new therapeutic approach for IBD by administration of antisense MIF oligonucleotides in conjugation with schizophyllan (SPG), a member of the glucan family. SPG specifically binds Dectin-1 expressed in antigen-presenting cells (APCs), and the antisense MIF/SPG complex is incorporated into the cells. In in vivo experiments of colitis models in mice, we found that intraperitoneal administration of the complex ameliorated the clinical signs of colitis and improved the histological scores. This novel therapy designed to knock down the MIF production in APCs is expected to be clinically applicable for the treatment of IBD.